Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m² in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m².

Autor: Barley, Kevin, Sanchez, Larysa, Cho, Hearn J., Parekh, Samir, Madduri, Deepu, Richter, Joshua, Isola, Luis, Goldstein, Talia, Dhadwal, Amishi, Zarychta, Katarzyna, Sanchez, Gillian Morgan, Catamero, Donna, Verina, Daniel, Florendo, Erika, Yum, Moon‐hee, La, Lisa, Gullie, Jude, Chan, Elaine, Jagannath, Sundar, Chari, Ajai

Publikováno v: American Journal of Hematology; Feb2020, Vol. 95 Issue 2, pE51-E54, 4p

Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m ² in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m ² .

Autor: Barley K; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Sanchez L; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Cho HJ; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Parekh S; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Madduri D; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Richter J; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Isola L; Bone Marrow and Stem Cell Transplant Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Goldstein T; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Dhadwal A; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Zarychta K; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Sanchez GM; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Catamero D; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Verina D; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Florendo E; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Yum MH; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., La L; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Gullie J; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Chan E; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Jagannath S; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Chari A; Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

Publikováno v: American journal of hematology [Am J Hematol] 2020 Feb; Vol. 95 (2), pp. E51-E54. Date of Electronic Publication: 2019 Dec 22.